Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S44-S53
DOI: 10.4103/ijmpo.ijmpo_175_17
Original Article

Clinical Profile of Acute Myeloid Leukemia in North India and Utility of Nontransplant Measures in its Management

Nadeem Shoket
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Javvid Muzamil
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Tasneef Banoo Zargar
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Burhan Wani
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Vishal Toka
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Javid Rasool Bhat
Departments of Clinical Hematology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Gull Mohammad Bhat
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
,
Aejaz Aziz Shiekh
Departments of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Introduction: Acute myeloid leukemia (AML) is a clonal accumulation of myeloid precursors in body tissues, which ultimately leads to bone marrow failure. This is an 8-year prospective, observational study in which 254 patients were enrolled. Aim of the Study: To document the clinical profile of AML and differential outcome in M3 versus non-M3 phenotype and to see impact of different variables on its survival. Methods: Patients enrolled in the study were examined, evaluated, and given standard 3:7 induction protocol, and acute promyelocytic leukemia (APML) patients were given the ICAPL 2006 protocol. Results: In our study, males outnumbered females and most of our patients were in 20–60 years of age group. The better prognosis was in patients who were in the second decade of life. Total leukocyte count and platelet count had a significant impact on the survival of the a patient. Bone marrow morphology of M3 type has extremely good prognosis and was the most common FAB type seen in our study. Flow cytometric markers such as CD15, CD33, CD117, and myeloperoxidase had positivity among 90% of patients. Overall survival is around 40% in whole-study group, 87% in APML group, and 16.5% in non-M3 group. There are still unmet needs in managing the non-M3 patients in resource-constraint countries where allogenic transplant and newer drugs have the least access. For improving the outcome in M3 AML, further newer molecules such as Flt3 and PIK3 inhibitors are being used in trials. Conclusion: There are still unmet needs in managing the non-M3 patients in resource-constraint countries where allogenic transplant and newer drugs have the least access. For improving the outcome in M3 AML, further newer molecules such as Flt3 and PIK3 inhibitors are being used in trials.

Keywords

Acute myeloid leukemia - acute promyelocytic leukemia - cluster differentiation - event-free survival - myelodysplastic leukemia - myeloperoxidase - overall survival - reverse-transcriptase polymerase chain reaction - total leukocyte count


Publication History

Article published online:
24 May 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K. Acute myelogenous leukemia. Williams Hematology. Malignant Diseases. Part IX. Ch. 87 7th ed. McGraw-Hill; 2006
    Google Scholar
  • 2 Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302
    CrossrefPubMedGoogle Scholar
  • 3 Smith MT, Skibola CF, Allan JM, Morgan GJ. Causal models of leukaemia and lymphoma. IARC Sci Publ 2004; 157: 373-92
    Google Scholar
  • 4 Ghosh S, Shinde SC, Kumaran GS, Sapre RS, Dhond SR, Badrinath Y. et al. Haematologic and immunophenotypic profile of acute myeloid leukemia: An experience of Tata memorial hospital. Indian J Cancer 2003; 40: 71-6
    CrossrefPubMedGoogle Scholar
  • 5 Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL. et al. editors SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute; Available from: http://www.seer.cancer.gov/csr/1975_2014/based/on/November/2016/SEER/data/submission/posted/to/the/SEER/web/site/. [Last accessed on 2017 Apr].
    Google Scholar
  • 6 Smith RE, Bryant J, DeCillis A, Anderson S. National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195-204
    CrossrefPubMedGoogle Scholar
  • 7 Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: Report from an international workshop. Genes Chromosomes Cancer 2002; 33: 395-400
    CrossrefPubMedGoogle Scholar
  • 8 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405
    CrossrefPubMedGoogle Scholar
  • 9 Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424-47
    CrossrefPubMedGoogle Scholar
  • 10 NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia: Version 1.2017. National Comprehensive Cancer Network. Available from: http://www.NCCN/Clinical/Practice/Guidelinesin/Oncology/Acute/Myeloid/Leukemia/Version/1.2017. [Last accessed on 2017 Feb 24].
    Google Scholar
  • 11 Swaminathan R, Rama R, Shanta V. Childhood cancers in Chennai, India, 1990-2001: Incidence and survival. Int J Cancer 2008; 122: 2607-11
    CrossrefPubMedGoogle Scholar
  • 12 Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA. et al. Acute myeloid leukaemia: Challenges and real world data from India. Br J Haematol 2015; 170: 110-7
    CrossrefPubMedGoogle Scholar
  • 13 Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE. et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-5
    CrossrefPubMedGoogle Scholar
  • 14 Pouls RK, Shamoon RP, Muhammed NS. Clinical and haematological parameters in adult AML patients: A four year experience at Nanakaly hospital for blood diseases. Zanco J Med Sci 2012; 16: 2012
    CrossrefGoogle Scholar
  • 15 Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW. et al. Smoking adversely affects survival in acute myeloid leukemia patients. Int J Cancer 2012; 130: 1451-8
    CrossrefPubMedGoogle Scholar
  • 16 Cheng Y, Wang Y, Wang H, Chen Z, Lou J, Xu H. et al. Cytogenetic profile of de novo acute myeloid leukemia: A study based on 1432 patients in a single institution of China. Leukemia 2009; 23: 1801-6
    CrossrefPubMedGoogle Scholar
  • 17 Ayesh M, Khassawneh B, Matalkah I, Alawneh K, Jaradat S. Cytogenetic and morphological analysis of de novo acute myeloid leukemia in adults: A single center study in Jordan. Balkan J Med Genet 2012; 15: 5-10
    CrossrefPubMedGoogle Scholar
  • 18 Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L. et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-18
    CrossrefPubMedGoogle Scholar